Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
暂无分享,去创建一个
Bernd Hauck | Bruce L Levine | David L Porter | Richard Aplenc | Michael Kalos | D. Teachey | S. Grupp | D. Porter | B. Levine | M. Kalos | C. June | J. F. Wright | B. Hauck | D. Barrett | R. Aplenc | Stephan A Grupp | David Barrett | Susan R Rheingold | David T Teachey | Anne Chew | J Fraser Wright | Michael C Milone | Carl H June | A. Chew | S. Rheingold | M. Milone | Richard | J. F. Wright | Aplenc | Bruce L. Levine | Carl H. June | David L. Porter | J. Fraser Wright | Carl H June | David L. Porter | J. F. Wright | Michael C Milone | J. Fraser Wright | J. Fraser Wright | Michael C. Milone | J. F. Wright
[1] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[2] P. Hari,et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] G. Janka. Familial and acquired hemophagocytic lymphohistiocytosis , 2006, European Journal of Pediatrics.
[4] L. Frankel,et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Shuster,et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. , 1994, The New England journal of medicine.
[6] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[7] Hao Liu,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.
[8] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[9] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[10] Rob Pieters,et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. , 2008, Cancer cell.
[11] R. Collins,et al. Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.
[12] G. Garcia-Manero,et al. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.
[13] Yongmin Tang,et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome , 2008, British journal of haematology.
[14] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[15] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[16] M. Fujimoto,et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. , 2012, The Journal of investigative dermatology.
[17] D. Maloney,et al. CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results , 2012 .
[18] G. Koretzky,et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. , 2011, The Journal of clinical investigation.
[19] R. Pieters,et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. , 2005, Cancer research.
[20] Robert H. Collins,et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[22] Dafydd G. Thomas,et al. Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation , 2010, Clinical Cancer Research.
[23] Jinjuan Wang,et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.
[24] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[27] K. Kreuzer,et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.